Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study is planned to evaluate safety and efficacy of Levolet in patients with complicated UTI
A complicated urinary tract infection is a urinary infection occurring in a patient with a structural or functional abnormality of the genitourinary tract.
Fluoroquinolones have been recommended as the antimicrobials of choice for the empirical treatment of complicated urinary tract. Levofloxacin is a broad spectrum agent, which is known to demonstrate good clinical efficacy against urinary tract infection (UTI).
There is no published evidence available on the empirical use of Levofloxacin 500 mg OD and its optimal duration of therapy in patients with Complicated Urinary Tract Infections (cUTI). The present study evaluates the efficacy and safety, and optimal duration of therapy of levofloxacin 500 mg OD in patients with complicated UTI.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Levofloxacin 5 days | Experimental | Levolet 500 mg given for 5 days |
|
| Levofloxacin 10 days | Active Comparator | Levolet 500 mg given for 10 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Levofloxacin | Drug | Levolet 500 mg OD for 5 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with clinical cure rates at test of cure visit (TOC) defined as follows- Cure: a complete resolution of clinically significant signs & symptoms | Cure: a complete resolution of clinically significant signs & symptoms | Baseline to 5 days |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with microbiological eradication at test of cure visit (TOC) | Eradication: All uropathogens present at ≥105 CFU/ml at baseline had been reduced to <104 CFU/ml | Baseline to 5 days and upto 10 days |
| No. of adverse events in entire study duration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| SUHAS S KHANDARKAR | Contact | 04049002419 | 2419 | suhassk@drreddys.com |
| Name | Affiliation | Role |
|---|---|---|
| Dr Ilyas Tungiskhanovich | Scientific Centre of Urology named after B.U Dzharbusynov 2, Basenov street, Almaty 050060, Republic of Kazakhstan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scientific Centre of Urology named after B.U Dzharbusynov 2, Basenov street, | Recruiting | Almaty | 050060 | Kazakhstan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D064704 | Levofloxacin |
| ID | Term |
|---|---|
| D015242 | Ofloxacin |
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Levofloxacin | Drug | Levolet 500 OD for 10 days |
|
|
Type and total number of AEs recorded in study duration |
| Baseline to EOT visit (Baseline to 15 days) |
| Percentage of patient compliant to therapy in each study arm. | Percentage of patients compliant to study treatment | Baseline to EOT visit (Baseline to 15 days) |
| Percentage of patient samples sensitive to levofloxacin in each study arm. | Percent sensitivity | Baseline to EOT (Baseline to 15 days) |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D011804 |
| Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |